Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tazarotene · 1 trial · 2 indications
General overall safety and tolerability of oral GRI-0621 as compared to placebo will be assessed by evaluating the following safety parameters: * Adverse events (occurrence and type) * Clinical Laboratory Measurements (normal/abnormal) * Vital signs (normal/abnormal)
| Arm | Type | Description |
|---|---|---|
| GRI-0621 | EXPERIMENTAL | GRI-0621 (tazarotene) 4.5mg, administered orally once daily (QD) |
| Placebo | EXPERIMENTAL | Placebo 4.5mg, administered orally once daily (QD) |
| Name | Type | Description |
|---|---|---|
| Tazarotene (GRI-0621) | DRUG | Oral 4.5mg soft gel capsule |
| Placebo | DRUG | Oral 4.5mg soft gel capsule |
Inclusion Criteria: 1. Male or female subjects 40 through 85 years of age, inclusive. 2. Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines for IPF. 3. FVC \> 50% predicted value within 4 weeks of Screening. 4. FEV1/FVC ratio \> 0.65 within 4 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
Tazarotene is an investigational small molecule being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). It is being developed by GRI Bio, Inc. and is currently in Phase 2 clinical development. The drug is intended to modulate biomarkers and inhibit NKT1 cells in patients with IPF.
Tazarotene targets NKT1 cells, a type of immune cell involved in the pathogenesis of Idiopathic Pulmonary Fibrosis. By inhibiting NKT1 cells, the drug aims to modulate biomarkers associated with the disease. This mechanism is being evaluated in a Phase 2 clinical trial.
Tazarotene is being developed by GRI Bio, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug for the treatment of Idiopathic Pulmonary Fibrosis. GRI Bio, Inc. is the sponsor of the ongoing Phase 2 study.
Tazarotene is in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its safety and efficacy in patients with IPF.
Tazarotene has been studied in a Phase 2 clinical trial with the identifier NCT06331624. This trial, titled 'Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF,' enrolled 35 participants and was conducted in the United States, Australia, and the United Kingdom. The study has been completed.
Yes, Tazarotene is also known as GRI-0621. In clinical trials, the drug is referred to as GRI-0621, as seen in the Phase 2 study NCT06331624. Both names refer to the same investigational small molecule being developed for Idiopathic Pulmonary Fibrosis.